JP2014500724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500724A5 JP2014500724A5 JP2013538972A JP2013538972A JP2014500724A5 JP 2014500724 A5 JP2014500724 A5 JP 2014500724A5 JP 2013538972 A JP2013538972 A JP 2013538972A JP 2013538972 A JP2013538972 A JP 2013538972A JP 2014500724 A5 JP2014500724 A5 JP 2014500724A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- protein
- homologous
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 159
- 102000004169 proteins and genes Human genes 0.000 claims description 138
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 239000012634 fragment Substances 0.000 claims description 68
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 60
- 230000002163 immunogen Effects 0.000 claims description 57
- 125000000539 amino acid group Chemical group 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 26
- 108091026890 Coding region Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 21
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 16
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 10
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 10
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 6
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 6
- 102000046689 human FOLH1 Human genes 0.000 description 5
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 2
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317610P | 2010-11-12 | 2010-11-12 | |
| US61/413,176 | 2010-11-12 | ||
| US41781710P | 2010-11-29 | 2010-11-29 | |
| US61/417,817 | 2010-11-29 | ||
| PCT/US2011/060592 WO2012065164A2 (en) | 2010-11-12 | 2011-11-14 | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016026602A Division JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500724A JP2014500724A (ja) | 2014-01-16 |
| JP2014500724A5 true JP2014500724A5 (enExample) | 2014-12-18 |
| JP6077450B2 JP6077450B2 (ja) | 2017-02-08 |
Family
ID=46051609
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538972A Active JP6077450B2 (ja) | 2010-11-12 | 2011-11-14 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2016026602A Active JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2017222784A Active JP7142427B2 (ja) | 2010-11-12 | 2017-11-20 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020046459A Active JP7572152B2 (ja) | 2010-11-12 | 2020-03-17 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020211554A Withdrawn JP2021045171A (ja) | 2010-11-12 | 2020-12-21 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2023160203A Pending JP2023171837A (ja) | 2010-11-12 | 2023-09-25 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2025178788A Pending JP2026012855A (ja) | 2010-11-12 | 2025-10-23 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016026602A Active JP6310952B2 (ja) | 2010-11-12 | 2016-02-16 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2017222784A Active JP7142427B2 (ja) | 2010-11-12 | 2017-11-20 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020046459A Active JP7572152B2 (ja) | 2010-11-12 | 2020-03-17 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2020211554A Withdrawn JP2021045171A (ja) | 2010-11-12 | 2020-12-21 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2023160203A Pending JP2023171837A (ja) | 2010-11-12 | 2023-09-25 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| JP2025178788A Pending JP2026012855A (ja) | 2010-11-12 | 2025-10-23 | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8927692B2 (enExample) |
| EP (3) | EP3536703B1 (enExample) |
| JP (7) | JP6077450B2 (enExample) |
| KR (5) | KR102131276B1 (enExample) |
| CN (2) | CN103314002B (enExample) |
| AU (1) | AU2011325893B2 (enExample) |
| BR (1) | BR112013011705B1 (enExample) |
| CA (1) | CA2817709C (enExample) |
| DK (1) | DK2638055T3 (enExample) |
| EA (1) | EA027315B1 (enExample) |
| ES (1) | ES2718846T3 (enExample) |
| MX (3) | MX346784B (enExample) |
| PL (1) | PL3536703T3 (enExample) |
| SI (1) | SI3536703T1 (enExample) |
| WO (1) | WO2012065164A2 (enExample) |
| ZA (1) | ZA201303390B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| EP3536703B1 (en) | 2010-11-12 | 2021-05-26 | The Trustees of the University of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| CA2871711A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| BR112015013700A8 (pt) * | 2012-12-13 | 2020-02-18 | Inovio Pharmaceuticals Inc | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição |
| CN104812401B (zh) * | 2012-12-13 | 2017-10-13 | 宾夕法尼亚大学理事会 | Wt1疫苗 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| MX369709B (es) * | 2013-03-15 | 2019-11-19 | Univ Pennsylvania | Vacunación mejorada contra tirosinasa. |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2928908C (en) * | 2013-11-01 | 2021-01-12 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| CN107427566B (zh) | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| SG11201808152PA (en) * | 2016-03-21 | 2018-10-30 | David Weiner | Dna antibody constructs and method of using same |
| JP6983819B2 (ja) * | 2016-06-03 | 2021-12-17 | エトゥビクス コーポレーション | 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法 |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| CN106581668B (zh) * | 2016-12-31 | 2020-03-24 | 广州姿生生物科技有限公司 | 一种抗原表位肽组合物及其应用 |
| CN117264963A (zh) * | 2017-12-13 | 2023-12-22 | 艾诺奥医药品有限公司 | 靶向prame的癌症疫苗和其用途 |
| CN111308327B (zh) * | 2019-12-02 | 2021-01-26 | 电子科技大学 | 模拟电路故障定位与故障元件参数辨识方法 |
| EP4306641A4 (en) * | 2021-02-05 | 2025-06-04 | ST Pharm Co., Ltd. | NEW NUCLEIC ACID MOLECULE |
| IT202400001212A1 (it) | 2024-01-23 | 2025-07-23 | Pratrivero S P A | Manufatto tessile predisposto per il riciclo e metodo per la produzione di tale manufatto |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| AU625584B2 (en) | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| DE69027313T2 (de) | 1989-03-31 | 1997-01-23 | Univ Washington | Impfstoffe enthaltende avirulente phop-type mikroorganismen |
| ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| JP4204642B2 (ja) * | 1992-11-05 | 2009-01-07 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 前立腺に特異的な膜抗原 |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| IL108449A (en) | 1993-01-26 | 2011-09-27 | Weiner David B | Assemblies and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| AU700371B2 (en) | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US6630305B1 (en) * | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| DK1023107T3 (da) | 1997-04-03 | 2006-12-27 | Electrofect As | Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US6833438B1 (en) * | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| EP2080802B1 (en) * | 1998-06-01 | 2017-03-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6136703A (en) | 1998-09-03 | 2000-10-24 | Micron Technology, Inc. | Methods for forming phosphorus- and/or boron-containing silica layers on substrates |
| KR100731820B1 (ko) | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| WO2001025272A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US20020081680A1 (en) * | 2000-04-17 | 2002-06-27 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| EP2287186B1 (en) | 2001-09-06 | 2014-12-31 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| EP1578371A4 (en) | 2002-08-19 | 2009-05-20 | Genentech Inc | COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT |
| CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| CA2526274C (en) * | 2003-05-30 | 2015-12-01 | Agensys, Inc. | Prostate stem cell antigen (psca) variants and subsequences thereof |
| ES2748130T3 (es) | 2003-05-30 | 2020-03-13 | Vgxi Inc | Dispositivos y métodos para la producción de un biomaterial |
| DK1711518T3 (da) * | 2004-01-23 | 2010-04-06 | Angeletti P Ist Richerche Bio | Vaccinebærere for chimpanse-adenovirus |
| AU2005249450A1 (en) * | 2004-05-27 | 2005-12-15 | Centocor, Inc. | Cynomolgus prostate specific antigen |
| KR100647847B1 (ko) | 2005-05-27 | 2006-11-23 | 크레아젠 주식회사 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 |
| CN101257920B (zh) * | 2005-06-21 | 2012-09-05 | 塞莱克蒂斯股份有限公司 | 与抗前列腺癌疫苗有关的方法和组合物 |
| BRPI0618850A2 (pt) * | 2005-11-21 | 2011-09-13 | Sanofi Pasteur Ltd | formulações de estabilização para vìrus recombinantes |
| EP2061814B1 (en) | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| JP5744719B2 (ja) * | 2008-04-04 | 2015-07-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
| WO2010027513A2 (en) * | 2008-09-08 | 2010-03-11 | Psma Development Company, Llc | Methods for killing psma-expressing, taxane-resistant cancer cells |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010050939A1 (en) * | 2008-10-29 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Improved hcv vaccines and methods for using the same |
| CA2740598C (en) * | 2008-11-17 | 2018-05-22 | Mathura P. Ramanathan | Antigens that elicit immune response against flavivirus and methods of using same |
| EP3536703B1 (en) * | 2010-11-12 | 2021-05-26 | The Trustees of the University of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
| WO2013067652A1 (en) * | 2011-11-10 | 2013-05-16 | Beijing Advaccine Biotechnology Co., Ltd. | Facilitator-dna combination vaccine |
| KR20220024974A (ko) * | 2016-09-30 | 2022-03-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Tert 면역원성 조성물 및 이를 이용한 치료 방법 |
-
2011
- 2011-11-14 EP EP19150850.6A patent/EP3536703B1/en active Active
- 2011-11-14 KR KR1020197023373A patent/KR102131276B1/ko active Active
- 2011-11-14 ES ES11839215T patent/ES2718846T3/es active Active
- 2011-11-14 KR KR1020137014954A patent/KR101939150B1/ko active Active
- 2011-11-14 CN CN201180064660.0A patent/CN103314002B/zh active Active
- 2011-11-14 BR BR112013011705-2A patent/BR112013011705B1/pt active IP Right Grant
- 2011-11-14 SI SI201131990T patent/SI3536703T1/sl unknown
- 2011-11-14 JP JP2013538972A patent/JP6077450B2/ja active Active
- 2011-11-14 MX MX2013005195A patent/MX346784B/es active IP Right Grant
- 2011-11-14 KR KR1020207019047A patent/KR102364214B1/ko active Active
- 2011-11-14 MX MX2018010616A patent/MX421208B/es unknown
- 2011-11-14 MX MX2016013461A patent/MX358725B/es unknown
- 2011-11-14 US US13/883,978 patent/US8927692B2/en active Active
- 2011-11-14 EP EP11839215.8A patent/EP2638055B1/en active Active
- 2011-11-14 AU AU2011325893A patent/AU2011325893B2/en active Active
- 2011-11-14 CN CN201610649676.2A patent/CN106434676B/zh active Active
- 2011-11-14 EP EP21175561.6A patent/EP3909973A3/en not_active Withdrawn
- 2011-11-14 EA EA201390689A patent/EA027315B1/ru not_active IP Right Cessation
- 2011-11-14 WO PCT/US2011/060592 patent/WO2012065164A2/en not_active Ceased
- 2011-11-14 DK DK11839215.8T patent/DK2638055T3/en active
- 2011-11-14 KR KR1020177035855A patent/KR102011026B1/ko active Active
- 2011-11-14 KR KR1020227004853A patent/KR102557275B1/ko active Active
- 2011-11-14 CA CA2817709A patent/CA2817709C/en active Active
- 2011-11-14 PL PL19150850T patent/PL3536703T3/pl unknown
-
2013
- 2013-05-09 ZA ZA2013/03390A patent/ZA201303390B/en unknown
-
2014
- 2014-11-24 US US14/552,030 patent/US9399056B2/en active Active
-
2016
- 2016-02-16 JP JP2016026602A patent/JP6310952B2/ja active Active
- 2016-07-11 US US15/207,271 patent/US9913885B2/en active Active
-
2017
- 2017-11-20 JP JP2017222784A patent/JP7142427B2/ja active Active
-
2018
- 2018-01-31 US US15/884,594 patent/US11045535B2/en active Active
-
2020
- 2020-03-17 JP JP2020046459A patent/JP7572152B2/ja active Active
- 2020-12-21 JP JP2020211554A patent/JP2021045171A/ja not_active Withdrawn
-
2021
- 2021-06-28 US US17/360,342 patent/US11980659B2/en active Active
-
2023
- 2023-09-25 JP JP2023160203A patent/JP2023171837A/ja active Pending
-
2024
- 2024-05-10 US US18/660,509 patent/US20250101399A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178788A patent/JP2026012855A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500724A5 (enExample) | ||
| Dalvie et al. | Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice | |
| ES2839880T3 (es) | Vacuna contra el VRS | |
| KR102713707B1 (ko) | 신규 다가 나노입자 기반 백신 | |
| Uppalapati et al. | A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo | |
| AU2015220369B2 (en) | UspA2 protein constructs and uses thereof | |
| CN114127101A (zh) | 用于治疗或预防呼吸道感染的亚单位疫苗 | |
| JP2009544333A5 (enExample) | ||
| JP2013526837A5 (enExample) | ||
| EP3436591B1 (en) | Adenoviral coat protein derived delivery vehicles | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| JP2014507146A5 (enExample) | ||
| EP1578922A2 (en) | Replikin peptides in rapid replication of glioma cells and in influenza epidemics | |
| JP2013518599A5 (enExample) | ||
| JP6406647B2 (ja) | 細胞性免疫誘導ワクチン | |
| JP2012515557A5 (enExample) | ||
| CN109575142B (zh) | 一种cd4辅助性t细胞表位融合肽及其疫苗 | |
| CN107847575A (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| CN117279659A (zh) | 人偏肺病毒疫苗 | |
| ES2780525T3 (es) | Proteínas quiméricas basadas en cyaa que comprenden un polipéptido heterólogo y sus usos en la inducción de respuestas inmunes | |
| JP2020502075A5 (enExample) | ||
| JP2022553258A (ja) | インフルエンザウイルスワクチン及びその使用 | |
| CN100588430C (zh) | 基于表位的SARS-Cov基因疫苗及其构建 | |
| JP2008500802A5 (enExample) |